Literature DB >> 29567757

HSCT for GATA2 deficiency across the pond.

Dennis Hickstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29567757      PMCID： PMC5865236          DOI： 10.1182/blood-2018-02-826461

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis.

Authors:  Neil P Rodrigues; Viktor Janzen; Randolf Forkert; David M Dombkowski; Ashleigh S Boyd; Stuart H Orkin; Tariq Enver; Paresh Vyas; David T Scadden
Journal:  Blood       Date:  2005-04-05       Impact factor: 22.113

2.  Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

Authors:  Shannon R McCurdy; Yvette L Kasamon; Christopher G Kanakry; Javier Bolaños-Meade; Hua-Ling Tsai; Margaret M Showel; Jennifer A Kanakry; Heather J Symons; Ivana Gojo; B Douglas Smith; Maria P Bettinotti; William H Matsui; Amy E Dezern; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Douglas E Gladstone; Lode J Swinnen; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

3.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

Authors:  Amy P Hsu; Elizabeth P Sampaio; Javed Khan; Katherine R Calvo; Jacob E Lemieux; Smita Y Patel; David M Frucht; Donald C Vinh; Roger D Auth; Alexandra F Freeman; Kenneth N Olivier; Gulbu Uzel; Christa S Zerbe; Christine Spalding; Stefania Pittaluga; Mark Raffeld; Douglas B Kuhns; Li Ding; Michelle L Paulson; Beatriz E Marciano; Juan C Gea-Banacloche; Jordan S Orange; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

4.  Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.

Authors:  Jennifer Grossman; Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Christa Zerbe; Katherine Calvo; Thomas Hughes; Fran Hakim; Kristen Cole; Mark Parta; Alexandra Freeman; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-09       Impact factor: 5.742

5.  Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.

Authors:  Imke H Bartelink; Arief Lalmohamed; Elisabeth M L van Reij; Christopher C Dvorak; Rada M Savic; Juliette Zwaveling; Robbert G M Bredius; Antoine C G Egberts; Marc Bierings; Morris Kletzel; Peter J Shaw; Christa E Nath; George Hempel; Marc Ansari; Maja Krajinovic; Yves Théorêt; Michel Duval; Ron J Keizer; Henrique Bittencourt; Moustapha Hassan; Tayfun Güngör; Robert F Wynn; Paul Veys; Geoff D E Cuvelier; Sarah Marktel; Robert Chiesa; Morton J Cowan; Mary A Slatter; Melisa K Stricherz; Cathryn Jennissen; Janel R Long-Boyle; Jaap Jan Boelens
Journal:  Lancet Haematol       Date:  2016-10-13       Impact factor: 18.959

6.  In vivo T-depleted reduced-intensity transplantation for GATA2-related immune dysfunction.

Authors:  Eleni Tholouli; Katherine Sturgess; Rachel E Dickinson; Andrew Gennery; Andrew J Cant; Graham Jackson; Jim Lordan; Sophie Hambleton; Mary A Slatter; Venetia Bigley; Matthew Collin
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

7.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).

Authors:  Pia Ostergaard; Michael A Simpson; Fiona C Connell; Colin G Steward; Glen Brice; Wesley J Woollard; Dimitra Dafou; Tatjana Kilo; Sarah Smithson; Peter Lunt; Victoria A Murday; Shirley Hodgson; Russell Keenan; Daniela T Pilz; Ines Martinez-Corral; Taija Makinen; Peter S Mortimer; Steve Jeffery; Richard C Trembath; Sahar Mansour
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

8.  Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.

Authors:  Mark Parta; Nirali N Shah; Kristin Baird; Hind Rafei; Katherine R Calvo; Thomas Hughes; Kristen Cole; Meg Kenyon; Bazetta Blacklock Schuver; Jennifer Cuellar-Rodriguez; Christa S Zerbe; Steven M Holland; Dennis D Hickstein
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-03       Impact factor: 5.742

9.  Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.

Authors:  Rachel Emma Dickinson; Helen Griffin; Venetia Bigley; Louise N Reynard; Rafiqul Hussain; Muzlifah Haniffa; Jeremy H Lakey; Thahira Rahman; Xiao-Nong Wang; Naomi McGovern; Sarah Pagan; Sharon Cookson; David McDonald; Ignatius Chua; Jonathan Wallis; Andrew Cant; Michael Wright; Bernard Keavney; Patrick F Chinnery; John Loughlin; Sophie Hambleton; Mauro Santibanez-Koref; Matthew Collin
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

10.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330
  10 in total
  3 in total

Review 1.  Germline Predisposition to Hematolymphoid Neoplasia.

Authors:  Olga K Weinberg; Frank Kuo; Katherine R Calvo
Journal:  Am J Clin Pathol       Date:  2019-08-01       Impact factor: 2.493

2.  Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency.

Authors:  Diana X Nichols-Vinueza; Mark Parta; Nirali N Shah; Jennifer M Cuellar-Rodriguez; Thomas R Bauer; Robert R West; Amy P Hsu; Katherine R Calvo; Seth M Steinberg; Luigi D Notarangelo; Steven M Holland; Dennis D Hickstein
Journal:  Br J Haematol       Date:  2021-09-27       Impact factor: 8.615

3.  Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.

Authors:  John C Molina; Julie M Asare; Laura Tuschong; Robert R West; Katherine R Calvo; Rebecca Persky; Alison M Boyce; Dima A Hammoud; Steven M Holland; Dennis Hickstein; Nirali N Shah
Journal:  Pediatr Blood Cancer       Date:  2020-12-27       Impact factor: 3.838
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.